We recently published an article titled Jim Cramer’s Game Plan: 15 Stocks in Focus. In this article, we are going to take a ...

Wall Street analysts forecast that Bristol Myers Squibb (BMY) will report quarterly earnings of $1.46 per share in its upcoming release, pointing to a year-over-year decline of 14.1%. It is ...

BMY is looking to turn its business around, banking on the strong uptake of new drugs. The recent spate of positive regulatory updates also bodes well for the stock. We recommend investors to wait for ...

Bristol-Myers Squibb gets rated a hold, as I see future value in its clinical portfolio and pipeline, particularly ...

R Squared Ltd purchased a new position in Bristol-Myers Squibb (NYSE:BMY – Free Report) in the 4th quarter, according to its ...

Analysts at Zacks Research cut their Q1 2025 EPS estimates for Bristol-Myers Squibb in a research report issued on Wednesday, January 29th. Zacks Research analyst E. Bagri now forecasts that the ...

Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended ...

View Bristol-Myers Squibb Company (BMY) current and estimated P/E ratio data provided by Seeking Alpha.

Bristol Myers (BMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bristol Myers (BMY) announced the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has ...